Debt mandate: USD 15m of asset-backed financing for an export manufacturing facility in Central Java, available as a senior secured term loan (six-year tenor, 24-month interest-only grace then 48-month amortisation, first-ranking mortgage over land, building and machinery) or as a sale-and-leaseback with buy-back (purchase at USD 15m against an indicative market value of USD 20m, seven-year leaseback and an operator buy-back right at USD 20m). Security is a 9.36 ha industrial complex on eight contiguous titles with rights to 2054, a 32,000 m² building and installed plant — USD 23.2m of fixed assets at book value, an indicative 65–75% LTV on land and building alone. Sponsor is an Asia-Pacific manufacturing group of about 30 years standing, 98% owner, supplying blue-chip global beverage and sportswear brands. The borrowing entity is pre-revenue and at production start-up, with the final manufacturing licence (IUI) pending. Blind teaser; identities and the data room follow an NDA.
Majority stake sale and capital raise: 65% of an Indonesian company that owns a DP2 deepwater drillship (DNV classed, 1,700 m water depth, 7,000 m drilling depth, 120 berths), now in the final stage of reactivation at Batam. Revenue is contracted before completion — a firm 180-day, one-well offshore drilling contract in the Natuna Sea with a Pertamina subsidiary, effective November 2025, valued at USD 54.3m at a day rate of USD 188,000; the contract sits with a three-party consortium of which the company is one member. USD 22.0m of reactivation has been funded and spent; the USD 27.1m completes the subsea scope and funds working capital to first revenue, targeted April 2027. Investor principal is repaid ahead of profit distribution. A USD 179m campaign pipeline is indicated but unawarded.
Sell-side process for 100% of the shares in a licensed Klinik Utama multidisciplinary outpatient clinic in Kwitang, Senen, Central Jakarta (Jakarta Pusat), opened in May 2024. Five service lines: general practice and medical check-up (MCU), internal medicine, physiatry and rehabilitation, physiotherapy, and obstetrics, with recurring corporate MCU clients. Trailing twelve-month revenue of IDR 1.15bn to July 2026 and a 4.9/5 patient rating across about 290 reviews. Full sale only.
Sell-side process for a Bank Indonesia PJP Category 1 licence holder with QRIS, e-wallet and payment gateway all live. Operating since 2020, cashflow positive, lock-up expired.
Sell-side process for a Bank Indonesia PJP Category 2 licence holder operating 10+ years, permitted for payment initiation/acquiring and fund transfer. Licence entity only — no system, customer book or operating business. AML/CFT rated Sangat Baik; PJP 1 upgrade recommended by the BI supervisor, not yet granted.
